RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kyorin Pharmaceutical Co Stock

Kyorin Pharmaceutical Co Revenue 2024

Kyorin Pharmaceutical Co Revenue

119.53 B JPY

Ticker

4569.T

ISIN

JP3247090008

In 2024, Kyorin Pharmaceutical Co's sales reached 119.53 B JPY, a 5.53% difference from the 113.27 B JPY sales recorded in the previous year.

The Kyorin Pharmaceutical Co Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2027e125.2841,03
2026e128.140,13
2025e126.4840,65
2024119.5343,01
2023113.2744,29
2022105.5346,85
2021102.950,17
2020109.9851,86
2019113.6250,53
2018110.6455,65
2017115.3755,93
2016119.4860,36
2015113.1258,81
2014111.461,36
2013107.0362,50
2012103.2364,23
2011104.0763,91
201099.7662,43
200990.8959,52
200881.0760,35
200777.0959,81
20060.37100,00
20053.3836,23

Kyorin Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kyorin Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kyorin Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kyorin Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kyorin Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kyorin Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kyorin Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kyorin Pharmaceutical Co’s growth potential.

Kyorin Pharmaceutical Co Revenue, EBIT and net profit per share

DateKyorin Pharmaceutical Co RevenueKyorin Pharmaceutical Co EBITKyorin Pharmaceutical Co Net Income
2027e125.28 B undefined0 undefined4.59 B undefined
2026e128.1 B undefined0 undefined5 B undefined
2025e126.48 B undefined0 undefined5.21 B undefined
2024119.53 B undefined6.01 B undefined5.32 B undefined
2023113.27 B undefined5.12 B undefined4.72 B undefined
2022105.53 B undefined5 B undefined3.93 B undefined
2021102.9 B undefined5.77 B undefined6.13 B undefined
2020109.98 B undefined7.49 B undefined6.15 B undefined
2019113.62 B undefined8.96 B undefined6.87 B undefined
2018110.64 B undefined8.81 B undefined6.57 B undefined
2017115.37 B undefined10.41 B undefined7.31 B undefined
2016119.48 B undefined19.64 B undefined13.64 B undefined
2015113.12 B undefined14.74 B undefined12.06 B undefined
2014111.4 B undefined17.61 B undefined12.03 B undefined
2013107.03 B undefined17.95 B undefined12.42 B undefined
2012103.23 B undefined14.46 B undefined9.23 B undefined
2011104.07 B undefined16.44 B undefined10.93 B undefined
201099.76 B undefined13.26 B undefined8.85 B undefined
200990.89 B undefined8.95 B undefined2.04 B undefined
200881.07 B undefined5.87 B undefined2.19 B undefined
200777.09 B undefined8.05 B undefined4.84 B undefined
2006366 M undefined143 M undefined20 M undefined
20053.38 B undefined-220 M undefined133 M undefined

Kyorin Pharmaceutical Co stock margins

The Kyorin Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kyorin Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kyorin Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kyorin Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Kyorin Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kyorin Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kyorin Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kyorin Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kyorin Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kyorin Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kyorin Pharmaceutical Co Margin History

Kyorin Pharmaceutical Co Gross marginKyorin Pharmaceutical Co Profit marginKyorin Pharmaceutical Co EBIT marginKyorin Pharmaceutical Co Profit margin
2027e43.01 %0 %3.67 %
2026e43.01 %0 %3.9 %
2025e43.01 %0 %4.12 %
202443.01 %5.02 %4.45 %
202344.29 %4.52 %4.17 %
202246.85 %4.74 %3.73 %
202150.17 %5.61 %5.96 %
202051.86 %6.81 %5.59 %
201950.53 %7.88 %6.05 %
201855.65 %7.96 %5.94 %
201755.93 %9.03 %6.33 %
201660.36 %16.43 %11.42 %
201558.81 %13.03 %10.66 %
201461.36 %15.81 %10.79 %
201362.5 %16.77 %11.61 %
201264.23 %14.01 %8.94 %
201163.91 %15.8 %10.5 %
201062.43 %13.29 %8.87 %
200959.52 %9.85 %2.24 %
200860.35 %7.24 %2.7 %
200759.81 %10.45 %6.28 %
2006100 %39.07 %5.46 %
200536.23 %-6.51 %3.94 %

Kyorin Pharmaceutical Co Aktienanalyse

What does Kyorin Pharmaceutical Co do?

Kyorin Holdings Inc is a Japanese holding company that was founded in September 2007. However, the company's history dates back to 1947 when Kyorin Pharmaceutical Co., Ltd. was established. Kyorin Holdings is a diversified company that operates in various sectors and business areas. The company's main activities include the development, production, and marketing of pharmaceutical products, medical devices, and healthcare products. In the pharmaceutical sector, Kyorin has been active since its inception. The company offers a wide range of products for various conditions such as asthma, allergies, or diabetes. Additionally, Kyorin is dedicated to developing medications for rarer diseases such as Fabry disease or amyotrophic lateral sclerosis (ALS). Another important business area of Kyorin is medical devices and accessories. The company primarily focuses on devices for the diagnosis and treatment of respiratory diseases and allergies. This includes inhalers, peak flow meters, and allergy tests. Healthcare is another significant business area of Kyorin Holdings. The company offers products for maintaining and strengthening the immune system, such as dietary supplements and probiotics. Kyorin also provides cosmetic products made from plant-based ingredients. One of Kyorin's current projects is the development of peptide-based immunotherapies for cancer. The company has already achieved promising results in preclinical research and plans to continue clinical trials in the coming years. The corporate philosophy of Kyorin emphasizes the importance of research and development. The company invests a significant portion of its annual revenue in research and development and strives to find innovative solutions for disease treatment. Kyorin also values collaboration with other companies and research institutions. The company has formed partnerships with other pharmaceutical and medical technology companies to work together on the research and development of new products. Kyorin Holdings Inc is a company that focuses on the development and marketing of products that contribute to improving health and well-being. The company's various business areas allow it to target different audiences and meet the needs of patients and customers in various fields. With its long-standing experience in the pharmaceutical and medical technology sectors and its commitment to innovation and research, Kyorin remains an important player in healthcare and is dedicated to improving the quality of life for people worldwide. Kyorin Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Kyorin Pharmaceutical Co's Sales Figures

The sales figures of Kyorin Pharmaceutical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Kyorin Pharmaceutical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Kyorin Pharmaceutical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Kyorin Pharmaceutical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Kyorin Pharmaceutical Co stock

How much revenue did Kyorin Pharmaceutical Co generate this year?

Kyorin Pharmaceutical Co has achieved a revenue of 119.53 B JPY this year.

How much was the turnover of the company Kyorin Pharmaceutical Co compared to the previous year?

The revenue of Kyorin Pharmaceutical Co has increased by 5.53% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Kyorin Pharmaceutical Co?

The revenue of Kyorin Pharmaceutical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Kyorin Pharmaceutical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Kyorin Pharmaceutical Co so important for investors?

The revenue of Kyorin Pharmaceutical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Kyorin Pharmaceutical Co pay?

Over the past 12 months, Kyorin Pharmaceutical Co paid a dividend of 52 JPY . This corresponds to a dividend yield of about 3.43 %. For the coming 12 months, Kyorin Pharmaceutical Co is expected to pay a dividend of 52.48 JPY.

What is the dividend yield of Kyorin Pharmaceutical Co?

The current dividend yield of Kyorin Pharmaceutical Co is 3.43 %.

When does Kyorin Pharmaceutical Co pay dividends?

Kyorin Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Kyorin Pharmaceutical Co?

Kyorin Pharmaceutical Co paid dividends every year for the past 22 years.

What is the dividend of Kyorin Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 52.48 JPY are expected. This corresponds to a dividend yield of 3.46 %.

In which sector is Kyorin Pharmaceutical Co located?

Kyorin Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kyorin Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kyorin Pharmaceutical Co from 12/1/2024 amounting to 20 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Kyorin Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Kyorin Pharmaceutical Co in the year 2023?

In the year 2023, Kyorin Pharmaceutical Co distributed 52 JPY as dividends.

In which currency does Kyorin Pharmaceutical Co pay out the dividend?

The dividends of Kyorin Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kyorin Pharmaceutical Co

Our stock analysis for Kyorin Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kyorin Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.